Drug intelligence / Profile preview

L-selenomethylselenocysteine

Development stage
Unknown
Lead developer
Sabinsa
Modality
Small Molecules
Administration
Oral
01

Overview

L-selenomethylselenocysteine (also known as Se-methyl-L-selenocysteine or MSC) is a naturally occurring organic selenium compound found in Allium and Brassica vegetables, such as garlic and broccoli. It is a highly bioavailable, non-protein-accumulating selenoamino acid that acts as a prodrug. Upon oral administration, it is metabolized by kynurenine aminotransferase 1 (KYAT1) / cysteine-S-conjugate β-lyase to generate methylselenol, a highly active anticancer and antioxidant metabolite. L-selenomethylselenocysteine has been evaluated in clinical trials (Phase I/II) as a chemopreventive agent for prostate and breast cancers, and as a chemosensitizer or protective agent to reduce chemotherapy-induced toxicities (such as mucositis). It is also widely marketed as a dietary supplement for antioxidant and immune support.

Brand names
MethySeleneMethySelene 5000 DCPMethySelene5000 DCPMethySelene-5000 DCPMethyl SelenoCysteine 5000 DCP
Other names
3-(methylseleno)-L-alanineL-Se-methylselenocysteineL-SeMCL-methylselenocysteineMeSeCysMSCSe-methyl-L-selenocysteineSe-methylseleno-L-cysteineSe-methylselenocysteineSeMCmethylselenocysteine
02

Targets

GPX1 (Glutathione peroxidase 1)GPX4 (Glutathione peroxidase 4)HIF1A (Hypoxia-inducible factor 1-alpha)KYAT1 (Kynurenine aminotransferase 1)TXNRD1 (Thioredoxin reductase 1)

Beyond the preview

Go deeper on L-selenomethylselenocysteine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on L-selenomethylselenocysteine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call